Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women

Epidemiology

Volumn 11, Issue 4, 2000, Pages 382-387

  García Rodríguez, Luis A ^a   Varas, Cristina ^b   Patrono, Carlo ^c  

^a Department of Pharmacoepidemiology   (Spain)

^b Global Epidemiology   (Spain)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Aspirin; Automated database; Coronary heart disease; Gender; Menopause; Myocardial infarction; Non aspirin nonsteroidal antiinflammatory drugs; Primary prevention

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; COMPETITIVE INHIBITION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; SEX DIFFERENCE; THROMBOCYTE AGGREGATION INHIBITION;

AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; POSTMENOPAUSE; PREVENTIVE MEDICINE;

EID: 0033933177     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001648-200007000-00004     Document Type: Article

References (23)

1. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-1294.
2. Patrono C, Coller B, Dalen JE, Fuster V, Gent M, Harker LA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 1998;114:470S-88S.
3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
4. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. Primary prevention of coronary heart disease in women. N Engl J Med 1995;332:1758-1766.
5. García Rodríguez LA, Pérez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45:419-425.
6. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991;302:766-768.
7. Van Staa TP, Abenhaim L. The quality of information recorded on a UK database of primary care records: a study of hospitalizations due to hypoglycemia and other conditions. Pharmacoepidemiol Drug Safety 1994;3:15-21.
8. Varas-Lorenzo C, García-Rodríguez LA, Pérez-Gutthann S, Duque-Oliart A. Hormone replacement therapy and incidence of acute myocardial infarction; a population-based nested case-control study. Circulation (in press).
9. Walker AM. Observation and Inference. Newton Lower Falls, MA: Epidemiology Resources Inc, 1991.
10. García Rodríguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists and other antihypertensive drugs. Arch Intern Med 1998;158:33-39.
11. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-135.
12. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet 1998;351:233-241.
13. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, Gilliland J, Doll R. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988;296:313-316.
14. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood, pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet 1998;351:1755-1762.
15. Born G. Effects of aspirin and warfarin on fatal and non-fatal heart attacks. Lancet 1999;354:1472.
16. Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 1991;266:521-527.
17. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61-109.
18. Thomson PL, Nidorf SM, Parsons RW, Jamrozik KD, Hobbs MST. The benefits of β-blockade at the time of myocardial infarction J Hypertens 1991;9:S3:5-7.
19. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987;69:180-186.
20. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366-1372.
21. Pattono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Davi G, Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985;72:1177-1184.
22. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
23. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGetald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999;96:272-277.